Boehringer Ingelheim premieres short film to raise awareness of pulmonary fibrosis in the UAE

Boehringer Ingelheim, a renowned research-focused pharmaceutical company, unveiled a brief film during a premiere in Dubai to heighten awareness of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), two severe lung disorders that significantly affect patients' daily routines. Esteemed pulmonology and rheumatology medical experts, including Dr Bassam Mahboub, vice president of the Emirates Thoracic Society, and Dr Shamma Al Nokhatha, president of the Emirates Society for Rheumatology, attended the event to emphasize the necessity of early detection of pulmonary fibrosis and its repercussions.

IPF and PPF are marked by persistent lung scarring, resulting in irreversible lung function decline and diminished oxygen intake. The exact cause of IPF remains unidentified, whereas PPF can arise in individuals suffering from other ailments, such as rheumatoid arthritis. Typical symptoms encompass a persistent dry cough, difficulty breathing, and exhaustion, often mistaken for aging, exhaustion, or lack of physical fitness.

If left untreated, PPF can escalate, making daily tasks challenging and elevating the mortality risk. Ousama Alhaj, Boehringer Ingelheim's general manager and head of human pharma in the Near East and UAE, noted that the company has been dedicated to respiratory health for generations, acknowledging that scientific advancement must align with heightened disease awareness and prompt diagnosis.

Alhaj expressed the company's intention to capitalize on recent advancements in pulmonary fibrosis care in the UAE by fostering greater recognition of IPF and PPF signs and encouraging earlier medical consultation, while simultaneously driving scientific progress and innovation in healthcare solutions. Although IPF and PPF are considered rare, together, they affect approximately 9.2 million individuals worldwide.

Their progressive nature underscores the importance of early detection, yet studies indicate that diagnosis may be delayed by one to two years. Dr Bassam Mahboub, vice president of the Emirates Thoracic Society, highlighted that pulmonary fibrosis care is at a crucial juncture, transitioning towards a future where early recognition, enhanced multidisciplinary assessment, and prompt action can become more consistent components of the patient journey.

The key challenge now is ensuring that a symptom as frequently dismissed as shortness of breath prompts further investigation rather than being ignored. Recognizing these changes earlier can better position patients to receive appropriate assessments and care. The awareness campaign materializes at a critical time for pulmonary fibrosis care following the recent approval of a new treatment option for IPF and PPF, marking a significant milestone after a decade without a new treatment demonstrating efficacy in IPF.

This progress represents a major advancement for those affected by these progressive diseases. The forthcoming chapter in pulmonary fibrosis care should prioritize both scientific advancements and their effective translation into earlier recognition and improved patient experiences. This entails bolstering awareness among patients, families, and healthcare professionals and ensuring that individuals with persistent symptoms are connected to the appropriate care at the right time.

Innovation plays a vital role in making a substantial impact for patients. Boehringer Ingelheim's history spans over a century, during which it has led in respiratory health, developing treatments for conditions like asthma, chronic obstructive pulmonary disease (COPD), and pulmonary fibrosis. Today, the company builds upon its extensive scientific expertise in respiratory diseases through ongoing research, development, and strategic collaborations aimed at advancing new therapies and enhancing outcomes for individuals with severe lung conditions.